0001209191-19-021059.txt : 20190322 0001209191-19-021059.hdr.sgml : 20190322 20190322173727 ACCESSION NUMBER: 0001209191-19-021059 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190320 FILED AS OF DATE: 20190322 DATE AS OF CHANGE: 20190322 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Neff Thomas B CENTRAL INDEX KEY: 0001623238 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36740 FILM NUMBER: 19700840 MAIL ADDRESS: STREET 1: C/O FIBROGEN, INC. STREET 2: 409 ILLINOIS ST. CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FIBROGEN INC CENTRAL INDEX KEY: 0000921299 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 409 ILLINOIS STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-978-1200 MAIL ADDRESS: STREET 1: 409 ILLINOIS STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94158 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-03-20 0 0000921299 FIBROGEN INC FGEN 0001623238 Neff Thomas B C/O FIBROGEN, INC. 409 ILLINOIS ST. SAN FRANCISCO CA 94158 1 1 0 0 Chief Executive Officer Common Stock 2019-03-20 4 M 0 6834 2.90 A 2596440 D Common Stock 2019-03-20 4 S 0 11134 55.14 D 2585306 D Common Stock 2019-03-20 4 S 0 7266 55.83 D 2578040 D Common Stock 2019-03-20 4 S 0 428 55.09 D 75006 I By Family Partnership Common Stock 2019-03-20 4 S 0 990 55.83 D 74016 I By Family Partnership Common Stock 2019-03-21 4 M 0 6834 2.90 A 2584874 D Common Stock 2019-03-21 4 S 0 9642 55.37 D 2575232 D Common Stock 2019-03-21 4 S 0 8758 55.85 D 2566474 D Common Stock 2019-03-21 4 S 0 1418 55.83 D 72598 I By Family Partnership Common Stock 20000 I By Spouse Common Stock 60946 I See footnote Stock Option (Right to Buy) 2.90 2019-03-20 4 M 0 6834 0.00 D 2020-06-09 Common Stock 6834 321216 D Stock Option (Right to Buy) 2.90 2019-03-21 4 M 0 6834 0.00 D 2020-06-09 Common Stock 6834 314382 D Shares sold pursuant to a 10b5-1 plan. The shares were sold at prices ranging from $54.48 to $55.47. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares were sold at prices ranging from $55.495 to $56.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares were sold at prices ranging from $54.89 to $55.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares were sold at prices ranging from $55.59 to $56.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares were sold at prices ranging from $54.65 to $55.64. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares were sold at prices ranging from $55.65 to $56.18. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares were sold at prices ranging from $55.32 to $55.98. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP. Fully vested. /s/ Dorothy Pacini, Attorney-in-fact 2019-03-22